Neratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product in the world approved for intensive adjuvant therapy after treatment with HER2-positive breast cancer with trastuzumab (Herceptin) to reduce the risk of recurrence. The applicable population is to complete the standard trastuzumab adjuvant treatment of patients with undeveloped disease but high-risk factors.
For breast cancer patients who have completed standard trastuzumab (Herceptin, Herceptin) adjuvant therapy, disease progression, but high-risk factors
Product Name: Hernix
Generic Name: Neratinib
medicine Pack Size: 180’s
Available Strengths : 40 mg
Categories: irreversible tyrosine kinase inhibitor
Manufacturer: Beacon Pharmaceuticals Ltd.